FIGURE 1



20
15
10
5
0
-5
-10
-15
Mean % variation vs baseline 10 days
Japanese placebo
Japanese 200mg q.d.
Caucasian placebo
Caucasian 200 mg q.d.
[Total cholesterol]
[HDL]
[LDL]

FIGURE 2



Mean% variation vs baseline
40
35
30
25
20
15
10
5
0
placebo
30 mg qd
75 mg qd
150 mg qd
300mg qd
[total cholesterol]
[HDL]
[LDL]

FIGURE 3



25
20
15
10
5
0
-5
Mean% CFB
placebo
50 mg (N=82) q.d.
100 mg (N=85) q.d.
200 mg (N=86) q.d.
25 mg (N=86) b.i.d.
50 mg (N=85) b.i.d.
100 mg (N=84) b.i.d.
[total cholesterol]
[HDL]
[LDL]

FIGURE 4



14
12
10
8
6
4
2
0
-2
Mean % CFB
0
2
4
6
8
10
12
Week
Placebo
50 mg
100 mg
200 mg
2x25 mg
2x50 mg
2x100 mg

FIGURE 5



25
20
15
10
5
0
-5
Mean % CFB
0
2
4
6
8
10
12
Week
placebo
50 mg
100 mg
200 mg
2x25 mg
2x50 mg
2x100 mg

FIGURE 6



4
2
0
-2
-4
-6
-8
-10
Mean % CFB
0
2
4
6
8
10
12
Week
Placebo
50 mg
100 mg
200 mg
2x25 mg
2x50 mg
2x100 mg

FIGURE 7A




FIGURE 7B




FIGURE 8A




FIGURE 8B




FIGURE 9A




FIGURE 9B




FIGURE 10




FIGURE 11A




FIGURE 11B




FIGURE 12A




FIGURE 12B




FIGURE 13A




FIGURE 13B




FIGURE 14A




FIGURE 14B




FIGURE 15A




FIGURE 15B




FIGURE 16A




FIGURE 16B




FIGURE 17A




FIGURE 17B




FIGURE 18



6
4
2
0
-2
-4
-6
-8
Mean % CFB
0
2
4
6
8
10
12
14
16
18
20
22
24
Week
Placebo to 100 mg
Continued 50 mg in resp.
50 mg to 100 mg in non-resp.
Continued 100 mg
Continued 200 mg

FIGURE 19A




FIGURE 19B




FIGURE 20



Screened N=1276
Not eligible at screening N=677
Randomized N=599
Not exposed N=5
Randomized & exposed N=594
Placebo N=86
50 mg N=82
100 mg N=85
200 mg N=86
2x25 mg N=86
2x50 mg N=85
2x100 mg N=84
Placebo N=53
100 mg N=15
2x50 mg N=15
50 mg N=57
100 mg N=19
100 mg N=78
200 mg N=80
2x25 mg N=60
2x50 mg N=17
2x50 mg N=80
2x100 mg N=83
W0-12
W13-24

FIGURE 21



Screenings N=635
Not eligible at screening N=348
Randomized N=287
Not exposed N=4
Randomized & exposed N=283
Placebo N=72
50 mg N=72
100 mg N=70
200 mg N=69
100 mg N=65
50 mg N=52
100 mg N=15
100 mg N=67
200 mg N=66
W0-12
W13-24

FIGURE 22



Screenings N=322
Not eligible at screening N=147
Randomized N=175
Not exposed N=1
Randomized & exposed N=174
200 mg N=130
Discontinued:
- Safety: 4 (3%)
- Efficacy: 9 (7%)
- Other: 6 (5%)
- Total: 19 (15%)
W10 completed N=111 (85%)
Placebo N=44
Discontinued:
- Safety: 3 (7%)
- Efficacy: 3 (7%)
- Other: 1 (2%)
- Total: 7 (16%)
W10 completed N=37 (84%)

FIGURE 23A




FIGURE 23B




FIGURE 24A




FIGURE 24B




FIGURE 25A




FIGURE 25B




FIGURE 26A




FIGURE 26B




FIGURE 27



Screened subjects N=311
Not eligible at screening N=137
Randomized & exposed N=174
No data N=2
Placebo N=44
200 mg N=128
Responders
Non-responders
Placebo N=15
100 mg N=22
Responders Rerandomized
Non-responders Rerandomized
Placebo N=14
100 mg N=30
200 mg N=30
Placebo N=9
200 mg N=25
W0-W10
W10-W20

FIGURE 28A




FIGURE 28B




FIGURE 29A




FIGURE 29B




FIGURE 30A




FIGURE 30B




FIGURE 31A




FIGURE 31B

